BACKGROUND: Immediate-release morphine sulfate (IRMS) remains the standard
treatment for breakthrough cancer pain (BTCP), but its onset of effect does not match the …

Purpose Despite progress in treatments, cancer pain remains underestimated, poorly
assessed and under-treated. Prescribing strong opioids, because of their specificities …

Treatment of cancer pain is generally based on the three-step World Health Organization
(WHO) pain relief ladder, which utilizes a sequential approach with drugs of increasing …

BTP represents a serious problem reported by many cancer patients despite receiving
regular use of opioids. Subgroups of breakthrough pain have been identified. Different …

Supplemental dosing of an opioid is the main treatment suggested to manage breakthrough
pain in cancer patients. The intravenous route has been proven to be safe and effective …

The care of patients suffering from advanced cancer is not limited in the hospital setting. It
continues at home where the burden of care is borne by specific individuals. The aim of the …

The aim of this study was to evaluate the clinical response to a combination of intrathecal
morphine and levobupivacaine in advanced cancer patients who were highly opioid …

Background: In clinical practice the major role of opioid drugs is the management of
malignant and nonmalignant pain. The primary aim of this study is to evaluate the trend in …

The heterogeneity of the palliative care population represents challenges to research
methodology, including study design, informed consent (and ethical issues in general) …

As newly developed synthetic enzymes with exceptional catalytic capabilities and
outstanding stability, nanozymes have drawn considerable interest in the realm of sensing …